Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials-Reference-Cited by-同舟云学术

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

Published:2015-10 Issue:10001 Volume:386 Page:1341-1352
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Publisher

Elsevier BV

Subject

General Medicine

Reference27 articles.

1. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials;Lancet,2011

2. Long-term effects of continuing adjuvant tamoxifen to 10 years vs stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial;Davies;Lancet,2013

3. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years vs stopping at 5 years in 6,953 women with early breast cancer;Gray;J Clin Oncol,2013

4. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors vs tamoxifen;Dowsett;J Clin Oncol,2010

5. ASCO clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor positive breast cancer;Burstein;J Clin Oncol,2010

Cited by 1131 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New treatment strategy for early hormone receptor-positive HER2-negative breast cancer: updated results of adjuvant abemaciclib trial in operable and locally advanced breast cancer;Medical alphabet;2024-09-08

2. Abemaciclib Therapy Using the MonarchE Criteria Results in Large Numbers of Excess Axillary Node Clearances—Time to Pause and Reflect?;Cancers;2024-09-04

3. Venous thromboembolism in women with hormone-dependent breast cancer. To continue or discontinue hormonal treatment? Insights from the RIETE registry;Thrombosis Research;2024-09

4. Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole;European Journal of Cancer;2024-09

5. Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor–Positive, Early-Stage Breast Cancer;Journal of Clinical Oncology;2024-09-01